Plain-English translation of NCT01746836 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called ponatinib for people with chronic myeloid leukemia (a blood cancer) whose disease has become resistant to or intolerant of standard first-line treatments. Ponatinib is a targeted therapy designed to work differently than previous medications, potentially helping patients whose cancer has stopped responding to earlier drugs. The study will track how well the medication works and what side effects patients experience over time.
When people with chronic myeloid leukemia stop responding to standard treatments, they need new options. This trial exists to see whether this medication can help patients whose disease has become resistant to earlier drugs and to understand how safe and effective it is.
You likely qualify if…
You likely don't qualify if…
You would take this medication as a daily pill by mouth for up to 5 years, as long as your disease is not getting worse and you are tolerating the treatment well. You'll have regular clinic visits and blood tests to monitor how well the medication is working and to check for any side effects. The study will track your response to treatment, how long remissions last, and your overall health over time.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States